[The cause of the secondary reaction in the intravenous use of administered immunoglobulin].
D000707:Anaphylaxis / Q000139:chemically induced / Q000209:etiology*; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis; D003167:Complement Activation; D004342:Drug Hypersensitivity / Q000209:etiology; D005174:Factor XII / Q000096:biosynthesis; D015956:Factor XIIa; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects*; D007070:Immunoglobulin A / Q000276:immunology; D007126:Immunoglobulin Allotypes / Q000276:immunology; D007073:Immunoglobulin E / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000276:immunology; D007136:Immunoglobulins / Q000008:administration & dosage*; D007249:Inflammation / Q000209:etiology; D010446:Peptide Fragments / Q000096:biosynthesis; D010974:Platelet Aggregation; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects
D000888:Antibodies, Anti-Idiotypic; D007070:Immunoglobulin A; D007126:Immunoglobulin Allotypes; D007074:Immunoglobulin G; D007136:Immunoglobulins; D010446:Peptide Fragments; D011310:Preservatives, Pharmaceutical; D007073:Immunoglobulin E; D005174:Factor XII; D015956:Factor XIIa
Ursachen von Nebenwirkungen bei der Anwendung von intravenös applizierbaren Immunglobulinen.